Association of body mass index and abdominal adiposity with atherogenic lipid profile in Nigerians with type 2 diabetes and/or hypertension

Olufemi A. Fasanmade, Ifedayo A. Odeniyi, Christiana O. Amira, Njideka U. Okubadejo

Department of Medicine, College of Medicine, University of Lagos, Nigeria

ABSTRACT

Background: We explored the relationship between anthropometric indices (obesity and abdominal adiposity) and the presence of an atherogenic lipid profile in Nigerians with major cardiovascular risk factors (type 2 diabetes mellitus-T2DM, hypertension-HBP, and concomitant disease). Materials and Methods: Using a prospective design, 278 patients with T2DM, HBP, or concomitant disease, attending out-patient diabetes and hypertension clinics at a tertiary institution in Nigeria were evaluated. All patients were cholesterol-lowering oral medication naïve. Demographic and clinical data and anthropometric measurements were documented. Fasting lipid profiles were measured in all cases. The cut-off points for defining dyslipidaemia were: Elevated total cholesterol (TC) (mg/dL) ≥200, elevated low-density lipoprotein cholesterol (LDL-C) (mg/dL) ≥100, low high-density lipoprotein cholesterol (HDL-C) (mg/dL) <40 for men and <50 for women, and high triglycerides (TG) (mg/dL) ≥150 mg/dL. Results: We found a significantly higher mean BMI (kg/m²) in the HBP group (30.5 ± 6.0) compared to T2DM (28.1 ± 5.9) and concomitant HBP and T2DM groups (29.4 ± 5.2) (ANOVA; \( P = 0.02 \)). The most frequent dyslipidaemia was elevated LDL-C in 92 (96.8%) HBP, 73 (85.9%) T2DM and 79 (80.6%) concomitant disease. The frequency of low HDL-C was highest in T2DM (68.2%) compared to the other 2 groups (\( P = 0.03 \)). Conclusions: Only TG levels were found to relate with any anthropometric index (waist circumference (WC) in this case) in Nigerians with major cardiovascular risk factors in this study. Routine anthropometric indices do not appear to be reliable surrogates for atherogenicity measured by abnormalities in TC, LDL-C and HDL-C.

Key words: Atherogenic profile, blacks, diabetes, hypertension, metabolic syndrome, Nigerians

INTRODUCTION

Anthropometric and biochemical risk factors have been associated with an increased risk of adverse cardiovascular outcome.\(^1\)\(^,\)\(^2\) Anthropometric indices (particularly body mass index-BMI and waist circumference-WC) are widely employed as predictors of future cardiovascular events such as heart disease and stroke.\(^3\)\(^,\)\(^6\) Both measurements are relatively simple to use and have been employed in field surveys as surrogate markers of total body fat composition (BMI) and visceral fat composition (WC) and by extension, as measures of risk of cardiovascular disease (CVD). Apart from these anthropometric measures, the presence of certain patterns of lipid abnormalities (an atherogenic lipid profile) has also been consistently identified as a strong determinant of cardiovascular health.\(^7\)\(^-\)\(^9\) Elevated total cholesterol, low HDL cholesterol, high LDL cholesterol, hypertriglyceridaemia and abnormal cholesterol ratios are associated with an increased risk of atherosclerosis.

These risk factors for CVD are particularly pertinent in persons with diseases such as type 2 diabetes mellitus (T2DM) and hypertension (HBP), either occurring alone or concomitantly. The Adult Treatment Panel (ATP) III cholesterol guidelines emphasise the importance of assessment and intervention in persons at increased CVD risk, focusing on the primary prevention in persons with multiple risk factors.\(^10\) In resource-limited populations, it is important to ascertain methods of reducing resource utilisation by identifying credible alternatives or surrogates of CVD risk. Such recommendations, however, need to
The mean BMI (kg/m²) was calculated as weight (kg) divided by height (m²). Obesity was defined according to the World Health Organization (WHO) guidelines, as a BMI ≥30 kg/m². Elevated waist circumference (abdominal adiposity) was regarded as WC ≥102 cm for men and ≥88 cm for women, while elevated WHR was defined as WHR ≥0.90 for men and ≥0.80 for women. Lipid profile was measured in the fasting state and all samples were analysed in the research laboratory of the Department of Medicine, College of Medicine, University of Lagos. Plasma triglycerides and total cholesterol levels were determined using standard enzymatic methods and an automated analyser, while high-density lipoprotein cholesterol (HDL-C) was measured by the dextran sulphate-magnesium precipitation procedure. Low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald formula.

In order to characterise the lipid values as normal or abnormal, the Adult Treatment Panel (ATP) III criteria were used. Total cholesterol (mg/dL) ≥200 was categorised as elevated total cholesterol. LDL values (mg/dL) ≥100 were categorized as elevated LDL. HDL cholesterol (mg/dL) was classified as low if <40 for men and <50 for women. Triglycerides (TG) (mg/dL) levels ≥150mg/dL were categorised as elevated TG.

Data were analysed using the Statistical Package for the Social Sciences (SPSS®) version 13.0 for Windows. Continuous variables (age, WC, BMI, WHR and lipid values) are presented as means ± standard deviations (SD) and compared using Analysis of variance (ANOVA) with posthoc Bonferroni analysis. Categorical variables (gender, presence or absence of obesity and abdominal adiposity, abnormal lipid classification e.g., hypercholesterolaemia, low HDL cholesterolemia, high LDL-C) are presented as proportions and compared using Yates corrected X² test. Multiple linear regression analysis was used to explore the association between the lipid parameters and anthropometric indices (BMI and WC). Age (years) was also included as an independent variable in the regression model. Multiple regression analyses were conducted for the combined analyses of all the cases, and also in subgroup analyses based on the disease states (T2DM only, HBP only and concomitant disease only). Level of significance was set at a P < 0.05.

RESULTS

The baseline characteristics of the patients with T2DM, HBP and concomitant disease are shown in Table 1. The patients with concomitant disease were significantly older (P < 0.001) than the other two subgroups at the time of the study. In posthoc analysis, the significant difference was found to be due to the difference between the mean ages of T2DM and concomitant disease (P = 0.000) and HBP and concomitant disease groups (P = 0.005), with no significant difference between T2DM and HBP (P = 0.61). The mean BMI (kg/m²) differed significantly across the three groups (P = 0.02), with posthoc analysis revealing the difference as being due to the disparity between the T2DM and HBP group (P = 0.01), compared to T2DM and concomitant (P = 0.37) and HBP and concomitant (P = 0.49). Differences in the WC (cm) and WHR across the three groups are also shown in Table 1. Most of the significant difference in WC was shown to be due to the difference between T2DM and HBP (P = 0.009) compared to T2DM and concomitant group (P = 0.01) or HBP and concomitant group (P = 1.00) in posthoc analysis. Also, the difference in WHR across the three groups was found to be due to the difference between T2DM and HBP (P = 0.01) compared to T2DM and concomitant group (P = 0.01) or HBP and concomitant group (P = 1.00) in posthoc analysis.
disease states was shown to be due to differences between T2DM and concomitant group ($P = 0.005$), in contrast to the T2DM and HBP ($P = 0.13$) and HBP and concomitant group ($P = 0.70$). All lipid comparisons yielded $P > 0.05$ in posthoc Bonferroni analysis. The fasting lipid profiles of the three groups were not significantly different.

Table 2 shows the frequency of lipid abnormalities in the 3 groups. Elevated LDL-C was the most frequent dyslipidaemia, while hypertriglyceridaemia was least frequent. The frequency of low HDL cholesterol was highest in T2DM compared to the other groups. Metabolic syndrome, defined using the presence of at least three of the ATPIII criteria,\(^{10}\) was present in 187 (67.3\%) of the patients in this study. The frequency in T2DM, HBP and concomitant disease was 42 (49.4\%), 47 (49.5\%) and 98 (100\%), respectively ($P < 0.00001$).

The results of multiple regression analysis exploring the relationship between lipid parameters (as dependent variables) and BMI, WC and age (as independent variables) are shown in Tables 3 and 4. In the combined analyses of all cases, the only significant relationship demonstrated was a weak positive association ($P = 0.04$) between TG and WC [Table 3]. The trend of the association is shown in Table 3. Multiple regression in subgroup analyses of each disease state did not reveal any significant relationship between the lipid parameters and anthropometric indices.

### Table 1: Demographic, anthropometric and lipid profile characteristics of the study population

| Characteristic                  | Hypertension only (n=99) | Diabetes only (n=85) | Concomitant diabetes and hypertension (n=98) | Statistics |
|--------------------------------|--------------------------|----------------------|---------------------------------------------|------------|
| Mean age±SD (years)            | 54.2±11.2                | 52.1±11.4            | 59.1±9.9                                    | $F=10.35$ $P=0.000^*$ |
| Number of men (M to F ratio)   | 48 (1 to 1.02)           | 35 (0.7 to 2)        | 47 (0.92 to 2)                              | $X^2=6.66$ $P=0.44$ |
| Body mass index (kg/m\(^2\))   | 30.5±6.0                 | 28.1±5.9             | 30.4±7.2                                    | $F=4.11$ $P=0.02$ |
| Waist circumference (cm)       | 100.9±11.4               | 95.4±13.3            | 100.7±12.0                                  | $F=5.71$ $P=0.004^*$ |
| Waist-to-hip ratio             | 0.94±0.80                | 0.92±0.08            | 0.95±0.07                                   | $F=5.18$ $P=0.006^*$ |
| Total cholesterol (mg/dL)      | 208.2±24.2               | 218.8±25.4           | 215.3±26.2                                  | $F=0.94$ $P=0.39$ |
| Triglyceride (mg/dL)           | 44.6±12.0                | 43.6±20.4            | 42.9±14.6                                   | $F=0.29$ $P=0.75$ |
| LDL-cholesterol (mg/dL)        | 154.7±50.2               | 153.7±50.2           | 147.4±57.1                                  | $F=0.60$ $P=0.55$ |

*Significant differences ($P < 0.05$), HDL – High-density lipoprotein; LDL – Low-density lipoprotein

### Table 2: Frequency of lipid abnormalities categorised by subgroup of major cardiovascular disease

| Parameter\(^*\)                  | Hypertension only (n=99) | Diabetes only (n=85) | Concomitant diabetes and hypertension (n=98) | Statistics |
|----------------------------------|--------------------------|----------------------|---------------------------------------------|------------|
| Elevated total cholesterol       | 44 (45.3)                | 32 (37.6)            | 40 (40.8)                                   | $X^2=1.44$ $P=0.49$ |
| Elevated LDL cholesterol         | 92 (96.8)                | 73 (85.9)            | 79 (86.0)                                   | $X^2=12.24$ $P=0.002^*$ |
| Low HDL cholesterol              | 46 (48.4)                | 58 (68.2)            | 55 (56.1)                                   | $X^2=7.26$ $P=0.03^*$ |
| Elevated triglycerides           | 20 (21.1)                | 24 (27.4)            | 24 (27.4)                                   | $X^2=0.44$ $P=0.80$ |

\(^*\)The cut-off points for defining lipid abnormalities were: Elevated TC≥200 mg/dL, elevated LDL-C≥100 mg/dL, low HDL-C<40 mg/dL in men and <50 mg/dL in women and elevated TG≥150 mg/dL. **Statistics comparing all three groups, Comparison of frequency of low LDL-C in hypertension and diabetes ($X^2=5.69$; $P=0.02$), hypertension and concomitant disease ($X^2=12.03$; $P=0.0009$) and diabetes and concomitant disease ($X^2=0.96$; $P=0.45$). Comparison of frequencies for elevated TG between hypertension and diabetes ($X^2=6.43$; $P=0.01$), all other comparisons $P>0.05$. HDL – High-density lipoprotein; LDL – Low-density lipoprotein

### Table 3: Multiple linear regression analyses exploring the determinants of the lipid parameters in all three disease states combined

| Lipid parameter                | Independent variables | Standardised coefficient ($\beta$) | t       | P value |
|--------------------------------|-----------------------|-----------------------------------|---------|---------|
| Total cholesterol (mg/dL)      | BMI (kg/m\(^2\))     | −0.118                             | −1.40   | 0.16    |
|                                | Age (years)           | 0.019                              | 0.31    | 0.76    |
| HDL cholesterol (mg/dL)        | BMI (kg/m\(^2\))     | 0.055                              | 0.65    | 0.51    |
|                                | Age (years)           | −0.015                             | −0.18   | 0.85    |
| LDL cholesterol (mg/dL)        | BMI (kg/m\(^2\))     | −0.054                             | −0.64   | 0.52    |
|                                | Age (years)           | 0.131                              | 1.57    | 0.12    |
|                                | Waist circumference (cm) | −0.060                           | −0.99   | 0.32    |
| Triglycerides (mg/dL)          | BMI (kg/m\(^2\))     | −0.035                             | −0.43   | 0.67    |
|                                | Age (years)           | 0.171                              | 2.06    | 0.04*   |

\(^*\)The only significant relationship demonstrated was a weak positive association between triglyceride values and waist circumference [Table 1], HDL – High-density lipoprotein; LDL – Low-density lipoprotein; BMI – Body mass index
DISCUSSION

This prospective study of 278 Nigerians with major cardiovascular risk factors (HBP, T2DM, and concomitant disease) explored the relationship between easily measurable anthropometric indices of obesity and abdominal adiposity and lipid parameters. The major findings of this study are that although dyslipidaemia (most frequently elevated LDL-C), abdominal adiposity, and obesity are all prevalent in our patients with HBP and T2DM, the only association of any lipid parameter with an anthropometric index was between TG and WC, and that occurred only in combined analyses of the three disease states. Our study buttresses the findings of Isezuo et al.,19 in which the usefulness of HDL-C in predicting the presence of the metabolic syndrome in black Africans from Nigeria was evaluated. The study found that there was no association between HDL-C and BMI or HDL-C and WC. In a comparative study of body composition and its relationship to other markers of cardiovascular risk including lipids in black Haitians and whites, Désilets et al., concluded that the metabolic syndrome may be ethnicity-specific in its phenotype and that standard anthropometric indices (including BMI and WC) may not be as effective measures of cardiovascular risk in populations of African descent compared with whites, unless appropriate cut-off values are defined.20

We find it interesting that despite the fact that the least common dyslipidaemia in our study population was hypertriglyceridaemia, TG levels were the only lipid parameter related to any anthropometric index in our patients. The low prevalence of hypertriglyceridaemia in people of African ancestry is not novel to our study, and has been reported previously.21 Amongst black Africans, it is well-known that many females who have an excess cardiac morbidity over males have normal WHR even in the presence of varying degrees of obesity, possibly due to steatopygia, which masks the effect of abdominal fat when the WHR alone is used to assess adiposity.29

The association between abdominal adiposity measured by WC, and triglycerides in black men and women has been previously documented.26,27

Even at lower TG levels, the relationship of TG with insulin resistance and the inherent adverse effects are present in African Americans, implying that the ideal cut-off point for defining cardiovascular risk related to TG should be lowered in blacks. The results of our study draw attention to the lack of locally derived and applicable levels of adiposity based on anthropometric measurements. Presently, cut-off points for abdominal adiposity for Europid populations are applied to sub-Saharan black Africans in the absence of local cut-off points. This approach is potentially flawed as the cut-offs may not necessarily be representative of the status in all global populations or ethnicities. For instance, Asians have been found to develop adverse cardiovascular events even at values that would ordinarily be described as “normal anthropometric indices” in the Europids.28 This disparity has been linked to the excess storage of visceral fat in the Asians for every comparable level of BMI.29

As the cut-offs may not necessarily be representative of the status in all global populations or ethnicities. For instance, Asians have been found to develop adverse cardiovascular events even at values that would ordinarily be described as “normal anthropometric indices” in the Europids.28

The association between abdominal adiposity measured by WC, and triglycerides in black men and women has been previously documented.26,27

Even at lower TG levels, the relationship of TG with insulin resistance and the inherent adverse effects are present in African Americans, implying that the ideal cut-off point for defining cardiovascular risk related to TG should be lowered in blacks. The results of our study draw attention to the lack of locally derived and applicable levels of adiposity based on anthropometric measurements. Presently, cut-off points for abdominal adiposity for Europid populations are applied to sub-Saharan black Africans in the absence of local cut-off points. This approach is potentially flawed as the cut-offs may not necessarily be representative of the status in all global populations or ethnicities. For instance, Asians have been found to develop adverse cardiovascular events even at values that would ordinarily be described as “normal anthropometric indices” in the Europids.28 This disparity has been linked to the excess storage of visceral fat in the Asians for every comparable level of BMI.29

As the cut-offs may not necessarily be representative of the status in all global populations or ethnicities. For instance, Asians have been found to develop adverse cardiovascular events even at values that would ordinarily be described as “normal anthropometric indices” in the Europids.28

The association between abdominal adiposity measured by WC, and triglycerides in black men and women has been previously documented.26,27

Even at lower TG levels, the relationship of TG with insulin resistance and the inherent adverse effects are present in African Americans, implying that the ideal cut-off point for defining cardiovascular risk related to TG should be lowered in blacks. The results of our study draw attention to the lack of locally derived and applicable levels of adiposity based on anthropometric measurements. Presently, cut-off points for abdominal adiposity for Europid populations are applied to sub-Saharan black Africans in the absence of local cut-off points. This approach is potentially flawed as the cut-offs may not necessarily be representative of the status in all global populations or ethnicities. For instance, Asians have been found to develop adverse cardiovascular events even at values that would ordinarily be described as “normal anthropometric indices” in the Europids.28 This disparity has been linked to the excess storage of visceral fat in the Asians for every comparable level of BMI.29
Studies specifically designed to determine appropriate cut-off points to define normalcy of anthropometric indices in black Africans are pertinent. Such studies could be conducted using a population-based study modelled according, for instance, to the methods described by the Study of Health Assessment and Risk in Ethnic Groups (SHARE) investigators, in which principal components factor analysis was used to determine underlying latent factors associated with several clinical and biochemical markers in four ethnic groups (Europeans, Aboriginals, South Asians, and Chinese). In the interim before such data become available, we suggest that the International Diabetes Federation consensus of using the European recommendations be applied until such a time as specific data become available.

An interesting finding in this study was that, on average, persons with HBP alone had a higher mean BMI than those with T2DM or concomitant disease. The exact reason is unclear, but this may be related to weight loss associated with the diabetes (either as a result of reduced calorie intake due to emphasis on dietary control, and/or the use of appetite suppressing oral hypoglycaemic agents, or the effect of poor glycaemic control). We also hypothesise that the higher frequency of elevated LDL-C in HBP (in contrast to the other two groups) may be connected to dietary modifications regarding cholesterol intake implemented in diabetes, but often less emphasised to persons with HBP, and not necessarily an amelioration of the effects of DM by HBP in persons with concomitant disease.

In conclusion, our study re-emphasises the dilemma of delineating the lipid parameters reflective of atherogeneity using routine anthropometric indices specifically in black Africans at high risk of adverse cardiovascular events. Studies aimed at determining the anthropometric cut-off points that correlate with atherogenic lipid profiles in our environment remain pertinent; as such data are useful for public health preventive approaches, counselling, research and non-drug therapy. Our study is limited in that other measures of adiposity such as bioimpedance assessment and abdominal computerised tomography were not utilised, and thus their degree of correlation with lipid profile was not determined. We, however, emphasise that although imaging techniques can be utilised to determine total body fat and its distribution reliably, these measures are neither available nor readily applicable in the routine clinical setting, in contrast to anthropometric indices. Our study is also not generalisable to the population without these cardiovascular risk factors as it did not include a control group of healthy individuals.

REFERENCES

1. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60.
2. Watkins LO. Coronary heart disease and coronary disease risk factors in black populations in underdeveloped countries: The case for primordial prevention. Am Heart J 1984;108:850-62.
3. World Health Organization. Physical status: The use and interpretation of anthropometry. World Health Organization. Geneva: 1995.
4. Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, et al. AusDiab Steering Committee. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Inter Med 2002;254:555-63.
5. Okosun IS, Forrester TE, Rotimi CN, Osotimehin BO, Muna WF, Cooper RS. Abdominal obesity in six populations of West African descent: Prevalence and population attributable fraction of hypertension. Obes Res 1999;7:453-62.
6. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
7. Williams DP, Going SB, Lohman TG, Harsha DW, Srinivasan SR, Webber LS, et al. Body fatness and risk for elevated blood pressure, total cholesterol, and serum lipoprotein ratios in children and adolescents. Am J Public Health 1992;82:358-63.
8. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
9. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:912-21.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
11. Nicklas BJ, Penninx BW, Cesari M, Kritchevsky SB, Newman AB, Kanaya AM, et al. Health, Aging and Body Composition Study. Association of visceral adipose tissue with incident myocardial infarction in older men and women: The health, aging and body composition study. Am J Epidemiol 2004;160:741-9.
12. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: The Hoorn Study. Am J Clin Nutr 2003;77:1192-7.
13. Garrow JS, Webster J. Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 1985;9:147-53.
14. WHO consultation on the epidemic of obesity. Measuring obesity: Classification and description of anthropometric data. Warsaw: WHO Regional Office for Europe; 1987.
15. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-61.
16. US Department of Agriculture. Report of dietary guideline advisory committee for Americans; 1990. (USDA Publication No. 261-495/20124).
17. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. Isezuo SA. High density lipoprotein cholesterol useful in diagnosis of metabolic syndrome in native Africans with type 2 diabetes? Ethi Dis 2005;15:6-10.
20. Désilets MC, Garrel D, Couillard C, Tremblay A, Després JP, Bouchard C, et al. Ethnic differences in body composition and other markers of cardiovascular disease risk: Study in matched Haitian and White subjects from Quebec. Obesity (Silver Spring) 2006;14:1019-27.

21. Sumner AE, Vega GL, Genovese DJ, Finley KB, Bergman RN, Boston RC. Normal triglyceride levels despite insulin resistance in African Americans: Role of lipoprotein lipase. Metabolism 2005;54:902-9.

22. Stein E, Kushner H, Gidding S, Falkner B. Plasma lipid concentrations in nondiabetic, African American adults: Associations with insulin resistance and the metabolic syndrome. Metabolism 2007;56:954-60.

23. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic americans. Ann Epidemiol 2000;10:263-70.

24. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1139-58.

25. Reiner AP, Carlson CS, Ziv E, Iribarren C, Jaquish CE, Nickerson DA. Genetic ancestry, population sub-structure, and cardiovascular disease-related traits among African-American participants in the CARDIA Study. Hum Genet 2007;121:565-75.

26. Okosun IS, Cooper RS, Prewitt TE, Rotimi CN. The relationship of central adiposity to components of the insulin resistance syndrome in a biracial US population sample. Ethn Dis 1999;9:218-29.

27. Shen W, Punyanitya M, Chen J, Gallagher D, Albu J, Pi-Sunyer X, et al. Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring) 2006;14:727-36.

28. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44.

29. Okosun IS, Cooper RS, Rotimi CN, Osotimehin B, Forrester T. Association of waist circumference with risk of hypertension and type 2 diabetes in Nigerians, Jamaicans, and African-Americans. Diabetes Care 1998;21:1836-42.

30. Razak F, Anand SS, Shannon H, Vuksan V, Davis B, Jacobs R, et al. Defining obesity cut points in a multiethnic population. Circulation 2007;115:2111-8.

31. Banerjee D, Misra A. Does using ethnic specific criteria improve the usefulness of the term metabolic syndrome? Controversies and suggestions. Int J Obes (Lond) 2007;31:1340-9.